Roche (RHHBY) News Today $40.02 +0.65 (+1.65%) As of 03:59 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartDividendHeadlinesInsider TradesOwnershipShort InterestBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period BeiGene slips on decision to halt lung cancer programApril 3 at 3:11 PM | msn.comSarepta falls after clinical hold related to Elevidys trialsApril 3 at 3:11 PM | msn.comRoche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025April 3 at 3:11 PM | finance.yahoo.comGenentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer's at AD/PD 2025April 3 at 10:02 AM | businesswire.comRoche presents novel therapeutic and diagnostic advancements in Alzheimer's at AD/PD 2025April 3 at 9:30 AM | globenewswire.comRoche stock falls following Ocrevus trial updateApril 2 at 9:34 PM | investing.comRoche says MUSETTE trial did not meet primary endpointApril 2 at 9:34 PM | markets.businessinsider.comWhy Is Pharma Giant Roche Stock Trading Lower On Wednesday?April 2 at 3:12 PM | benzinga.comGenentech Provides Update on Phase III Ocrevus High Dose Study in People With Relapsing Multiple SclerosisApril 2 at 12:01 PM | businesswire.comRoche fails in bid to increase dose of MS drug OcrevusApril 2 at 11:48 AM | reuters.comRoche provides update on Phase III OCREVUS high dose study in people with relapsing multiple sclerosisApril 2 at 11:45 AM | globenewswire.comQuest Diagnostics Introduces HPV Specimen Self-Collection for Cervical Cancer ScreeningApril 2 at 7:06 AM | prnewswire.comSaratoga Research & Investment Management Trims Position in Roche Holding AG (OTCMKTS:RHHBY)Saratoga Research & Investment Management lessened its stake in Roche Holding AG (OTCMKTS:RHHBY - Free Report) by 6.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,174,306 shares of the company's stock after sellApril 1 at 5:52 AM | marketbeat.comShort Interest in Roche Holding AG (OTCMKTS:RHHBY) Decreases By 68.8%Roche Holding AG (OTCMKTS:RHHBY - Get Free Report) was the target of a significant decrease in short interest in March. As of March 15th, there was short interest totalling 3,665,700 shares, a decrease of 68.8% from the February 28th total of 11,741,100 shares. Approximately 0.1% of the company's stock are short sold. Based on an average trading volume of 5,260,100 shares, the short-interest ratio is currently 0.7 days.March 28, 2025 | marketbeat.comLarge pharma M&A deals stalling amid volatile policies, Reuters reportsMarch 27, 2025 | markets.businessinsider.comF. Hoffmann-La Roche Ltd: Roche Annual General Meeting 2025March 25, 2025 | finanznachrichten.deRoche Annual General Meeting 2025March 25, 2025 | globenewswire.comRoche abandons global diversity targets on concern over U.S. executive ordersMarch 19, 2025 | reuters.comOxford BioTherapeutics Enters into a Strategic Collaboration with Roche to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of CancerMarch 19, 2025 | globenewswire.comRoche (OTCMKTS:RHHBY) Sets New 1-Year High - Time to Buy?Roche (OTCMKTS:RHHBY) Sets New 1-Year High - Still a Buy?March 18, 2025 | marketbeat.comBig pharma fears drug price spikes in US-EU tariff spat, Reuters saysMarch 18, 2025 | markets.businessinsider.comRoche to present new data at MDA conference on EvrysdiMarch 17, 2025 | markets.businessinsider.comRoche to share latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association (MDA) 2025 conferenceMarch 17, 2025 | finance.yahoo.comRoche to share latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association (MDA) 2025 conferenceMarch 17, 2025 | globenewswire.comLineage Cell Therapeutics price target lowered to $3 from $4 at B. RileyMarch 14, 2025 | markets.businessinsider.comPharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline UpdateMarch 14, 2025 | msn.comShort Interest in Roche Holding AG (OTCMKTS:RHHBY) Increases By 467.7%Roche Holding AG (OTCMKTS:RHHBY - Get Free Report) was the recipient of a large growth in short interest in February. As of February 28th, there was short interest totalling 11,741,100 shares, a growth of 467.7% from the February 13th total of 2,068,200 shares. Based on an average trading volume of 9,269,800 shares, the short-interest ratio is presently 1.3 days. Currently, 0.2% of the company's stock are sold short.March 13, 2025 | marketbeat.comRoche signs $5.3 billion deal with Danish obesity drugmaker, Novo Nordisk stock slides 4%March 12, 2025 | msn.comRoche signs $5.3 billion deal with Danish obesity drugmaker, Novo stock slides 4%March 12, 2025 | msn.comWhy Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock DroppedMarch 12, 2025 | fool.comRoche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 BillionMarch 12, 2025 | investors.comZealand Pharma to pay $350M to Roche in petrelintide collaboration, license pactMarch 12, 2025 | markets.businessinsider.comRoche, Zealand Pharma enter $5.3B license deal for obesity treatmentMarch 12, 2025 | msn.comRoche and Zealand Pharma strike $5.3 billion deal for new obesity drug candidateMarch 12, 2025 | cnbc.comRoche takes big step in weight-loss field with $5.3 billion deal.March 12, 2025 | marketwatch.comRoche to develop, commercialize obesity drug with Zealand PharmaMarch 12, 2025 | reuters.comRoche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight and obesityMarch 12, 2025 | globenewswire.comRoche (OTCMKTS:RHHBY) Reaches New 1-Year High - Here's WhyRoche (OTCMKTS:RHHBY) Hits New 52-Week High - What's Next?March 11, 2025 | marketbeat.comRoche hires Novo Nordisk executive amid obesity drug push, Bloomberg reportsMarch 11, 2025 | markets.businessinsider.comRoche Holding AG (OTCMKTS:RHHBY) Given Average Rating of "Moderate Buy" by AnalystsRoche Holding AG (OTCMKTS:RHHBY - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six brokerages that are currently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recomMarch 9, 2025 | marketbeat.comPharma Stock Roundup: BAYRY's Q4 Results, ABBV's Obesity Deal & MoreMarch 7, 2025 | msn.comRoche announces launch of Roche Genentech Innovation Center Boston based at Harvard’s Enterprise Research Campus in AllstonMarch 7, 2025 | finance.yahoo.comRoche announces launch of Roche Genentech Innovation Center Boston based at Harvard's Enterprise Research Campus in AllstonMarch 7, 2025 | globenewswire.comGenentech receives FDA acceptance for Gazyva sBLAMarch 6, 2025 | markets.businessinsider.comGenentech gets FDA acceptance for its Lupus treatment's license applicationMarch 6, 2025 | msn.comRoche (OTCMKTS:RHHBY) Sets New 12-Month High - Here's WhyRoche (OTCMKTS:RHHBY) Sets New 52-Week High - Time to Buy?March 5, 2025 | marketbeat.comNoted Family Office Leader Stephan Roche Joins BanyanGlobal Family Business Advisors Partnership GroupMarch 5, 2025 | businesswire.comFDA accepts supplemental Biologics License Application for Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritisMarch 5, 2025 | finance.yahoo.comFDA Accepts Supplemental Biologics License Application for Genentech's Gazyva for the Treatment of Lupus NephritisMarch 5, 2025 | businesswire.comFDA accepts supplemental Biologics License Application for Roche's Gazyva/Gazyvaro for the treatment of lupus nephritisMarch 5, 2025 | globenewswire.com Remove Ads Get Roche News Delivered to You Automatically Sign up to receive the latest news and ratings for RHHBY and its competitors with MarketBeat's FREE daily newsletter. Email Address RHHBY Media Mentions By Week RHHBY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RHHBY News Sentiment▼0.320.60▲Average Medical News Sentiment RHHBY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RHHBY Articles This Week▼118▲RHHBY Articles Average Week Remove Ads Get Roche News Delivered to You Automatically Sign up to receive the latest news and ratings for RHHBY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies China Construction Bank News Airbus News EssilorLuxottica Société anonyme News Iberdrola News BNP Paribas News Nintendo News Atlas Copco News Vinci News Deutsche Post News Compass Group News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:RHHBY) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roche Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Roche With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RHHBY Stock Free RHHBY Stock Alerts